FGF401-(roblitinib)

oral reversible-covalent FGFR4 kinase inhibitor

first sel. FGFR4i in clinical studies; for HCC

from biochemical HTS and SBDD

J. Med. Chem., Oct. 1, 2020

Novartis, Basel, CH

FGF401 (roblitinib) is a highly selective, reversible-covalent inhibitor of the kinase FGFR4, a receptor that can drive progression of certain cancers. The Novartis team found that the FGFR4 protein has…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.